Trial Profile
Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs L-Acetylleucine (Primary)
- Indications GM2 gangliosidoses; Sandhoff disease; Tay-Sachs disease
- Focus Therapeutic Use
- Acronyms IB1001-202
- Sponsors IntraBio
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2022 Results assessing the efficacy and safety of N-Acetyl-L-Leucine in patients with GM2 gangliosidoses, published in the Neurology.
- 02 Aug 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.